The week in industry: Collaboration to develop first human-specific in vitro model of heart failure
This week: US FDA grants priority review for FGFR inhibitor for bile duct cancer, new drug approval to slow rate of pulmonary decline in systemic sclerosis patients and US$20 million for the launch of patient-partnered rare disease drug repurposing program.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>